Utrecht, The Netherlands, September, 2017 – U-PROTEIN EXPRESS B.V. is pleased to announce that it has completed a merger with ImmunoPrecise Antibodies Ltd., a Canadian company (TSX VENTURE: IPA) (OTC PINK: IPATF) to work cooperatively to offer both protein expression and greater antibody production to its customers thereby increasing and diversifying its service offerings. At the same time, a central element of the merger is that U-Protein Express and existing staff will continue to offer the same high-quality service to its customers.
About ImmunoPrecise Antibodies
ImmunoPrecise Antibodies provides its customers with custom antibody engineering and production services to support their research and development efforts. The services offered to customers include the development of mouse and rat monoclonal and rabbit recombinant monoclonal antibodies against a wide spectrum of antigens, as well as polyclonal antibodies, immunologically based assays, and solutions to challenges faced by clients in antibody related research and development. In addition, cryopreservation services are provided for the storage of valuable biological materials including hybridoma clones, plasmid constructs, and cell lines. The antibodies produced by ImmunoPrecise Antibodies target a wide variety of environmental, diagnostic and research applications.
About U-Protein Express
U-Protein Express is a privately held company based in Utrecht, The Netherlands and holds the rights to proprietary expression technology used in antibody production. U-Protein Express is a Contract Research Organization (“CRO”) that offers fast and large-scale production of (mammalian) recombinant proteins and antibodies for research and pre-clinical applications.
For further information please contact:
Martin Hessing, U-Protein Express B.V., Phone: +31-(0)30 253 7903, Life Science Incubator Utrecht Science Park, Yalelaan 62, 3484 CM Utrecht The Netherlands, email: email@example.com
For investor relations relating to ImmunoPrecise please contact:
Rob Gamley Phone: 1-604-689-7422 Email: firstname.lastname@example.org. Contact Financial Corp. 1450 – 701 West Georgia St. Vancouver, BC V7Y 1G5
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. ImmunoPrecise uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, the Company closing its acquisition of UProtein, completing the Financing, and such risks and uncertainties described in the Company’s Filing Statement dated December 13, 2016 which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, the Company undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.